Delivery Order SPE2DB22D3501-SPE2DB24FXC16

Award Date 9/25/24
Potential Completion Date 9/26/24
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a total ceiling value of $23,954.18 and covers the delivery of Remicade 100 mg vials. It is a firm fixed-price contract with an ultimate completion date of April 16, 2025. The contract is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a larger Indefinite...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,029.28 firm fixed-price contract is for the delivery of 100 mg vials of the medication Remicade. The contract has a completion date of June 25, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,268.66, is for the supply of Remicade 100 mg vials, a specialty medication. The contract has a period of performance through January 7, 2025 and is a Firm Fixed Price type. The contract was not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This is a $24,787.38 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 100 mg vials of the pharmaceutical product Remicade. The contract has an ultimate completion date of September 5, 2024. AmerisourceBergen is one of the largest pharmaceutical distributors in the United States and has been awarded numerous federal contracts to provide a wide range of pharmaceutical and medical supplies to support military treatment...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,024.40, is a firm fixed-price delivery order for the supply of 100 mg vials of the drug Remicade. The contract has a period of performance through March 7, 2025 and was awarded on March 6, 2025. This contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $7,518.30, is for the delivery of 4,568,139,088 units of the medication Remicade (100 mg vials). The contract is a Firm Fixed Price delivery order, with a performance period extending through May 6, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that...
This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to AmerisourceBergen Drug Corp for the delivery of Remicade 100 mg vials. The $11,943.91 firm fixed-price contract has an ultimate completion date of July 26, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this delivery order. The contract award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 100 mg vials of the pharmaceutical drug Remicade, with a ceiling value of $30,350.40 and a performance period through June 13, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen Drug Corp holds a significant...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of Remicade 100 mg vials, a prescription medication, with a ceiling value of $2,294.25 and a performance period ending on June 10, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,926.30, is for the procurement of Remicade 100 mg vials. This delivery order is issued under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, with a ceiling value of $999,999,999 and a period of performance through November 2026....
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FXC16
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is valued at $11,883.00 and is for the delivery of Remicade 100mg vials, a specialty medication. The contract has a completion date of September 26, 2024 and uses a firm-fixed-price pricing structure. This contract is not associated with a set-aside designation. AmerisourceBergen is the prime contractor and is responsible for supplying the required pharmaceutical product to support military treatment programs and facilities. The DLA is the primary funding agency for this contract, which aligns with their mission to provide medical commodities to the U.S. Department of Defense.

Generated 12/25/24, 9:11 AM